Table 2.

Selected outcomes beyond blood-pressure lowering for which angiotensin II receptor blockers have been evaluated versus non-angiotensin II receptor blocker treatment in randomized controlled trials.

	Atherosclerosis	Hypertensive LVH	2° Prevention post-MI	Stroke	Heart failure	Atrial fibrillation	Renoprotection
Losartan	+/−24–28	+ (LIFE)29–32	− (OPTIMAAL)33	+ (LIFE*)29,34 2° prevent: + (LIFE)34	+/− (ELITE/ ELITE II)35–37	1° prevent: + (LIFE)38,114	+ (RENAAL, JLIGHT, ROAD)39–41
Valsartan	+ (MARVAL-2, VIP)42,43	+44–47	+ (T-VENTURE, VALIANT)48,49,50	+ ( Jikei Heart*, KYOTO HEART*)51,52	+ (Val-HeFT)53,54	1° prevent: + (Val-HeFT)56 2° prevent: − (GISSI-AF)55	+ (VALERIA, SMART, HKVIN, MARVAL, MARVAL-2)42,57–60
Candesartan	+ (CENTRO, MITEC)61,106	+ (CATCH, CASE-J)62,63	− (E-COST)64	+ (SCOPE*)65,66 1° prevent: − (E-COST)64 2° prevent: + (E-COST)64	+ (RESOLVD, CHARM)67–74	2° prevent: − (CAPRAF)75	+/− (DIRECT, CENTRO)61,76
Irbesartan	+ (EPAS, ISLAND, SILVHIA)77–79	+ (SILVHIA, CVIP)80–82			+ (I-PRESERVE)83	2° prevent: +84,85	+/− (IRMA-2, IDNT, IMPROVE)86–88
Telmisartan	+89,90	+ (ONTARGET/ TRANSCEND)91		− (TRANSCEND*†)92 2° prevent: − (PRoFESS)93	+ (REPLACE)94	1° prevent: +95	+/− (INNOVATION, TRANSCEND, ONTARGET, DETAIL)96–99
Eprosartan	+100	+102		2° prevent: + (MOSES)104	+ (ADEPT)105
Olmesartan	+ (EUTOPIA)101	−103

Note: + designates that the study achieved its primary or secondary endpoint(s); − designates that study did not meet its primary or secondary endpoint(s); this table is a summary of fully published randomized controlled trial data (ie, no data from single-arm noncomparative trials were considered), with an emphasis on large-scale trials (when available). Additional smaller studies were considered in the absence of data from large-scale clinical trials.

LVH=left ventricular hypertrophy; MI=myocardial infarction.

^*Stroke data were not specific to primary or secondary prevention in the main analysis.

^†Stroke was evaluated in a post-hoc analysis, not as a prespecified endpoint.